Regeneron Pharmaceuticals (NASDAQ:REGN) Releases Earnings Results, Beats Estimates By $3.65 EPS

Key Points

• Regeneron significantly beat third-quarter expectations: Revenue rose 36.3% year over year to $5.12 billion, while non-GAAP EPS reached $20.07, exceeding consensus by $3.65.
• Key growth products delivered strong results: Dupixent sales rose 35% globally, U.S. EYLEA HD sales increased 62%, and Libtayo sales climbed 51%. Regeneron also expanded its Sanofi partnership, including a $1 billion upfront payment.
• Investors still face EYLEA and development-cost risks: Legacy U.S. EYLEA sales fell 41% amid biosimilar competition, and management expects R&D expenses to rise by a mid-teens percentage in 2027 as more than 15 Phase III trials advance.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) released its quarterly earnings data on Friday. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating the consensus estimate of $16.42 by $3.65, FiscalAI reports. The firm had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $4.56 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The firm's quarterly revenue was up 36.3% on a year-over-year basis. During the same period in the previous year, the company posted $11.83 earnings per share.

Here are the key takeaways from Regeneron Pharmaceuticals' conference call:

• Regeneron reported a strong third quarter, with total revenue up 36% to $5.1 billion and non-GAAP EPS up 70% to $20.07. Dupixent, EYLEA HD, and LIBTAYO each reached record quarterly sales.
• Dupixent sales grew 35% globally at constant currency to $6.5 billion, while U.S. EYLEA HD sales rose 62% to approximately $700 million and LIBTAYO sales increased 51% globally. Management expects continued EYLEA HD momentum and anticipates a potential prefilled-syringe approval before year-end.
• The pipeline produced encouraging data across several potential growth drivers, including approximately 70% liver-fat reduction for the genetically validated CIDEB siRNA, roughly 70% response rates for ubamatamab in low-grade serous ovarian cancer, and planned pivotal development for POTS and multiple myeloma programs.
• Regeneron expanded its Sanofi alliance to develop four next-generation, longer-acting type 2 inflammation antibodies, with Regeneron recording a $1 billion upfront payment in the fourth quarter and sharing future development costs and global profits equally.
• EYLEA’s U.S. sales fell 41% year over year to $400 million, with further low- to mid-teens sequential demand declines expected in the fourth quarter as aflibercept biosimilar competition increases. Regeneron also expects 2027 R&D expense to rise by a mid-teens percentage as it advances more than 15 Phase III trials.

Regeneron Pharmaceuticals Stock Performance

REGN stock traded up $108.99 on Friday, hitting $927.76. The company's stock had a trading volume of 2,276,224 shares, compared to its average volume of 819,198. Regeneron Pharmaceuticals has a 1 year low of $591.52 and a 1 year high of $935.35. The stock has a market cap of $95.52 billion, a price-to-earnings ratio of 22.93, a price-to-earnings-growth ratio of 1.37 and a beta of 0.16. The firm has a 50 day moving average of $791.28 and a two-hundred day moving average of $737.25. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q3 results significantly exceeded expectations: Revenue rose 36.3% year over year to $5.12 billion, versus the $4.56 billion consensus estimate. Non-GAAP EPS increased 70% to $20.07, beating expectations by roughly $3.65, while GAAP EPS rose 35% to $18.45. Regeneron Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: Dupixent remained the primary growth engine. Global Dupixent sales, recorded by partner Sanofi, increased 35% to $6.5 billion, comfortably exceeding market expectations and reinforcing the strength of Regeneron’s immunology franchise. Regeneron, Sanofi Surge As Dupixent Wallops Sales Forecasts
• Positive Sentiment: Other key products also delivered strong growth: U.S. EYLEA HD sales increased 62% to $699 million, and Libtayo global sales rose 51% to $550 million. Management said the company is positioned for one of its strongest years, helping drive investor enthusiasm. Regeneron Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: Pipeline and partnership catalysts improved the outlook. Regeneron expanded its Sanofi collaboration to include next-generation, long-acting immunology antibodies, including a $1.0 billion upfront payment, and advanced a Phase 2 cemiplimab combination study in skin cancer. Regeneron Expands Skin Cancer Pipeline With New Cemiplimab Combo Trial
• Neutral Sentiment: The stock’s move places it near a 52-week high, while analyst price-target changes have been mixed. Investors will likely focus on upcoming FDA decisions and continued execution across the pipeline. Regeneron Q3 2026 Earnings Call Transcript
• Negative Sentiment: Competition from biosimilars remains a risk for the older EYLEA 2 mg franchise, although management reported that sales have been resilient and EYLEA HD is growing rapidly.

Wall Street Analyst Weigh In

REGN has been the topic of a number of research reports. Cantor Fitzgerald increased their price objective on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an "overweight" rating in a report on Friday, July 31st. JPMorgan Chase & Co. raised their target price on Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the company an "overweight" rating in a research report on Tuesday, October 6th. Benchmark upgraded Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating and set a $185.00 price target on the stock in a report on Tuesday, July 7th. Leerink Partners increased their price target on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a "market perform" rating in a report on Monday, August 17th. Finally, Jefferies Financial Group lifted their target price on Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the company a "buy" rating in a research report on Thursday, October 1st. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $847.90.

Insider Activity

In other news, Director Huda Y. Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the transaction, the director directly owned 603 shares of the company's stock, valued at $512,550. This trade represents a 39.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 8,093 shares of company stock worth $6,506,845 in the last ninety days. 6.97% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.